[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvalent Inc Cl A (NUVL)

Nuvalent Inc Cl A (NUVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,990,533
  • Shares Outstanding, K 78,998
  • Annual Sales, $ 0 K
  • Annual Income, $ -425,380 K
  • EBIT $ -439 M
  • EBITDA $ -450 M
  • 60-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.11

Options Overview Details

View History
  • Implied Volatility 7.66% (-35.79%)
  • Historical Volatility 112.59%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 84.44% on 10/31/25
  • IV Low 7.66% on 06/09/26
  • Expected Move (DTE 9) 2.17 (1.76%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 25,017
  • Volume Avg (30-Day) 1,311
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 2,389
  • Open Int (30-Day) 1,919
  • Expected Range 120.90 to 125.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.44
  • Number of Estimates 6
  • High Estimate $-1.38
  • Low Estimate $-1.48
  • Prior Year $-1.31
  • Growth Rate Est. (year over year) -9.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.30 +41.12%
on 06/08/26
123.60 -0.33%
on 06/09/26
+17.92 (+17.02%)
since 05/08/26
3-Month
87.30 +41.12%
on 06/08/26
123.60 -0.33%
on 06/09/26
+20.88 (+20.40%)
since 03/09/26
52-Week
71.13 +73.20%
on 08/08/25
123.60 -0.33%
on 06/09/26
+47.11 (+61.93%)
since 06/09/25

Most Recent Stories

More News
Another sell-off for AI stocks sends Wall Street reeling

Another sell-off for artificial-intelligence stocks whipsawed Wall Street

NVDA : 206.95 (-0.81%)
$SPX : 7,360.10 (-0.62%)
SJM : 111.44 (+9.50%)
MU : 908.09 (-4.34%)
AMD : 467.30 (-4.70%)
NUVL : 123.15 (+39.17%)
$DOWI : 50,806.70 (+0.04%)
UNFI : 46.15 (-10.63%)
$IUXX : 28,903.90 (-1.74%)
MRVL : 262.16 (-9.24%)
Stocks Erase Early Gains as Chipmakers Turn Lower

The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures (ESM26...

ALK : 45.19 (+6.98%)
MPC : 258.21 (-2.99%)
MTN : 133.85 (-2.45%)
OXY : 56.17 (-2.28%)
FANG : 192.85 (-2.70%)
AMD : 467.30 (-4.70%)
NUVL : 123.15 (+39.17%)
NOVT : 163.90 (-0.27%)
SPY : 736.30 (-0.40%)
MU : 908.09 (-4.34%)
BKR : 63.67 (-1.80%)
ORCL : 205.86 (-2.81%)
GlaxoSmithKline Buys Cancer Drugmaker Nuvalent For $10.6 Billion

British pharmaceutical giant GlaxoSmithKline (GSK) is buying cancer drugmaker Nuvalent (NUVL) for $10.6 ...

NUVL : 123.15 (+39.17%)
Stocks Climb on an AI-Led Rebound

The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26...

ALK : 45.19 (+6.98%)
MPC : 258.21 (-2.99%)
SNDK : 1,668.15 (+1.59%)
MTN : 133.85 (-2.45%)
OXY : 56.17 (-2.28%)
FANG : 192.85 (-2.70%)
STX : 853.73 (-2.63%)
WDC : 516.91 (-1.90%)
NUVL : 123.15 (+39.17%)
NOVT : 163.90 (-0.27%)
SPY : 736.30 (-0.40%)
MU : 908.09 (-4.34%)
NUVL Stock Alert: Halper Sadeh LLC is Investigating Whether Nuvalent, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that...

NUVL : 123.15 (+39.17%)
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC

New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026

NUVL : 123.15 (+39.17%)
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting

Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trial

NUVL : 123.15 (+39.17%)
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results

NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC

NUVL : 123.15 (+39.17%)
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinityâ„¢ Platform

Multi-year global collaboration will leverage Guardant’s tissue and liquid biopsy portfolio to support clinical development and companion diagnostic strategies

GH : 128.23 (+2.67%)
NUVL : 123.15 (+39.17%)
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting

Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial

NUVL : 123.15 (+39.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 95.73
2nd Resistance Point 93.80
1st Resistance Point 91.15
Last Price 123.15
1st Support Level 86.57
2nd Support Level 84.64
3rd Support Level 81.99

See More

52-Week High 123.60
Last Price 123.15
Fibonacci 61.8% 103.56
Fibonacci 50% 97.36
Fibonacci 38.2% 91.17
52-Week Low 71.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.